Moderna MRNA Stock Drops Despite Market Gains: Important Facts to Note

Read Time:10 Minute, 36 Second

Dr. Kavita Patel joins ‘Fast Money’ to talk the impact of FDA and HHS changes on vaccines, public health policy, and more. Investors might also notice recent changes to analyst estimates for Moderna. Recent revisions tend to reflect the latest near-term business trends.

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day’s closing. Elsewhere, the Dow lost 1.33%, while the tech-heavy Nasdaq lost 0.13%. Enter your email address and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising. Despite efforts to control costs and improve financial efficiency, Moderna reported a net loss of $3.6 billion last year, or a loss of $9.28 per share, only modestly improved from a loss of $12.33 in 2023. Moreover, Wall Street analysts expect the company to remain unprofitable for the foreseeable future. Yet, not all is lost for Moderna, which maintains some key fundamental strengths, including an extensive pipeline of new product candidates and a strong balance sheet supporting a more positive, long-term outlook.

Table of Contents

The big picture for investors

Moderna scored higher than 85% of companies evaluated by MarketBeat, and ranked 136th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation. Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks.

Discover Financial Services (DFS) shares surged 7.5%, gaining the most of any S&P 500 stock on Monday, following indications that interim CEO J. Michael Shepherd will stay at the helm of the credit card issuer until Capital One Financial (COF) completes its acquisition of the company. In addition, a Friday report from The Capitol Forum Pepperstone Forex Broker suggested that the Department of Justice may be less inclined to challenge the merger despite concerns about a potential impact on consumers with no credit history. Select to analyse similar companies using key performance metrics; select up to four stocks.

Upgrade to MarketBeat All Access to add more stocks to your watchlist.
Yet, not all is lost for Moderna, which maintains some key fundamental strengths, including an extensive pipeline of new product candidates and a strong balance sheet supporting a more positive, long-term outlook.
Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups.
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration’s (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec…

Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement. Select to analyze similar companies using key performance metrics; select up to 4 stocks. American International Group (AIG) shares jumped 4.0% after the insurer’s board of directors approved plan to repurchase as much as $7.5 billion in the company’s common stock. The boost to the buyout plan coincided with AIG’s investor day event, which also saw the company issue upbeat growth targets. The the stock of biotechnology company has fallen by 24.4% in the past month, lagging the Medical sector’s loss of 8.46% and the S&P 500’s loss of 6.3%.

Global uptake candlestick patterns to master forex trading price action has been slow, with low demand for its current indication to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection, generating just $25 million in sales last year. It’s been nearly five years since Moderna (MRNA -1.89%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business. Shareholders haven’t been immune to a deep reset in the company’s expectations, with the stock losing 92% of its value from its all-time high. Shares of the pharmaceutical company have been trending downward since March 21, when Goldman Sachs downgraded the stock to “neutral” from “buy” and trimmed its price target.

Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
The the stock of biotechnology company has fallen by 24.4% in the past month, lagging the Medical sector’s loss of 8.46% and the S&P 500’s loss of 6.3%.
Although sales and profit topped estimates, the manufacturer of yoga attire provided an underwhelming outlook, noting diminished store traffic amid cautious consumer spending trends.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Its potential to transform oncology with a tailored immune approach could position Moderna as a major player in cancer therapeutics. Moderna (MRNA) shares tumbled 8.9%, logging the S&P 500’s weakest daily performance. The losses for the biotech stock came after Peter Marks, the top vaccine official at the Food and Drug Administration (FDA), announced his resignation from the agency.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus. overview xtrade The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Friday, March 21st.

Simultaneously, our latest consensus estimate expects the revenue to be $127.36 million, showing a 23.74% drop compared to the year-ago quarter. While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

MRNA Forecasts

UBS Group cut their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Finally, Berenberg Bank increased their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Moderna is recognized as a pioneer in messenger RNA (mRNA) technology, seen as a potential game changer in medicine. This technology uses the body’s cellular machinery to fight diseases by directing cells to produce proteins that trigger a specific immune response or address a particular health issue. As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases.

Food and Drug Administration had resigned, fanning worries over slowe… According to 20 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $54.47, which is an increase of 120.30% from the latest price. Discover which analysts rank highest on predicting the price target of MRNA.

MarketBeat Follows

Britain’s health regulator said on Friday it has approved Moderna’s vaccine to protect patients aged 60 and over against lower respiratory tract disease caused by the respiratory syncytial virus (RSV)… Shares of Lululemon Athletica (LULU) fell 3.4%, extending losses posted late last week in the wake of the company’s quarterly earnings release. Although sales and profit topped estimates, the manufacturer of yoga attire provided an underwhelming outlook, noting diminished store traffic amid cautious consumer spending trends. Lululemon’s CEO said the athletic wear company is making strides to address its persistent “newness” issues, which occur when a company’s product mix fails to entice consumers. Please bear with us as we address this and restore your personalised lists. Moderna faces a steep challenge in restoring investor trust in the stock market, and 2025 could prove to be a defining year for validating its business strategy.

Recent news: MRNA

MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources. Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S.

Finally, Exchange Traded Concepts LLC increased its holdings in shares of Moderna by 17.4% during the first quarter. Exchange Traded Concepts LLC now owns 30,693 shares of the company’s stock worth $870,000 after buying an additional 4,556 shares in the last quarter. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and non-profit The Motley Fool Foundation. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.15% decrease. The investment community will be closely monitoring the performance of Moderna in its forthcoming earnings report. The company is forecasted to report an EPS of -$2.91, showcasing a 5.21% upward movement from the corresponding quarter of the prior year.

While I believe it’s premature to adopt a decisively bullish stance on the stock, its opportunity in mRNA-based medicines makes it worth keeping on your radar and following company developments closely. Moderna’s near-term strategy focuses on driving the use of the mRESVIA and Spikevax vaccines, including through expanded indications. Nevertheless, its long-term potential hinges on the prospects of a pipeline of late-stage mRNA-based candidates, with a company goal of delivering 10 product approvals through 2027. In recent years, the challenge for the company has been managing the steep revenue decline following the pandemic’s peak. Shifting sentiment about the need for annual booster vaccination, competition from alternative therapeutics, and the withdrawal of emergency government funding for public immunization programs have left the COVID-19 vaccine business a shell of the cash cow it was just a few years ago. Please bear with us as we address this and restore your personalized lists.